Pravachol Generic Takes Its Toll On Bristol’s Pharma Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Global Sales of Bristol-Myers Squibb's blockbuster cholesterol drug Pravachol tumbled 48.3% to $323 mil. in the second quarter following the launch of generic pravastatin early in the quarter
You may also be interested in...
Bristol/Sanofi's Plavix Settlement Faces Justice Department Criminal Investigation
Bristol's conduct relating to the settlement with Apotex was "appropriate," CEO Dolan maintains.
Bristol/Sanofi's Plavix Settlement Faces Justice Department Criminal Investigation
Bristol's conduct relating to the settlement with Apotex was "appropriate," CEO Dolan maintains.
Teva Launches Generic Pravachol Following Appeals Court Dismissal Of Apotex
Watson concurrently launched an authorized generic of Bristol's pravastatin, but Ranbaxy's 80 mg ANDA remains on hold.